NanoString Technologies Hopes to Achieve FDA Clearance for Breast Cancer Test by 2012 | GenomeWeb

By Justin Petrone

NanoString Technologies has licensed a gene-expression signature from a coalition of university researchers that can be used to classify different breast cancer subtypes, according to a company official.

NanoString CEO Brad Gray told BioArray News this week that the firm intends to have the breast cancer intrinsic subtyping assay on the US market for clinical use in two years.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.